Section Arrow
SMMT.NASDAQ
- Summit Therapeutics
Quotes are at least 15-min delayed:2024/10/31 19:28 EDT
Last
 18.59
-0.06 (-0.32%)
Day High 
19.42 
Prev. Close
18.65 
1-M High
24.56 
Volume 
2.28M 
Bid
18.65
Ask
18.83
Day Low
18.095 
Open
18.75 
1-M Low
18.12 
Market Cap 
13.71B 
Currency USD 
P/E 25.11 
%Yield -- 
10-SMA 20.73 
20-SMA 20.33 
50-SMA 19.75 
52-W High 33.89 
52-W Low 1.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.11/-0.20
Enterprise Value
13.81B
Balance Sheet
Book Value Per Share
0.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.88M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:28 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.